Leap Therapeutics, Inc. (LPTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
LPTX Revenue Growth
Revenue Breakdown (FY 2021)
LPTX's revenue distribution by segment and geography for fiscal year 2021
By Product/Segment
LPTX Revenue Analysis (2014–2025)
As of May 8, 2026, Leap Therapeutics, Inc. (LPTX) generated trailing twelve-month (TTM) revenue of $209,000, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, LPTX's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $10.1 million in 2020.
Revenue diversification analysis shows LPTX's business is primarily driven by License (100%), and Royalty (0%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AGEN (+10.4% YoY), TGTX (+81.3% YoY), and RCUS (+67.4% YoY), LPTX has underperformed the peer group in terms of revenue growth. Compare LPTX vs AGEN →
LPTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| LPTXCurrent | $209,000 | -100.0% | - | - | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
LPTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $0 | - | $-41,067,000 | - |
| 2024 | $0 | - | $0 | - | $-70,057,000 | - |
| 2023 | $0 | - | $-427,000 | - | $-87,041,000 | - |
| 2022 | $0 | -100.0% | $0 | - | $-56,763,000 | - |
| 2021 | $1.5M | -85.1% | $1.5M | 100.0% | $-41,426,000 | -2761.7% |
| 2020 | $10.1M | +3.9% | $5.1M | 50.9% | $-3,446,000 | -34.3% |
| 2019 | $9.7M | - | $5.1M | 52.9% | $-3,476,000 | -35.9% |
| 2018 | $0 | - | $-49,000 | - | $-30,751,000 | - |
| 2017 | $0 | - | $-48,000 | - | $-32,352,000 | - |
| 2016 | $0 | - | $-25,000 | - | $-27,521,000 | - |
See LPTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LPTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LPTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLPTX — Frequently Asked Questions
Quick answers to the most common questions about buying LPTX stock.
Is LPTX's revenue growth accelerating or slowing?
LPTX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $209000.00. This reverses the prior growth trend.
What is LPTX's long-term revenue growth rate?
Leap Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is LPTX's revenue distributed by segment?
LPTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.